Rapid advances in the efficacy of chemotherapy regimens have led to increases in disease-free survival for many patients. This has led to an increased interest in the educing long-term side-effects of chemotherapy drugs, such as cardiotoxicity and peripheral neuropathy. Also, short term side effects, such as mucositis and myelosuppression, may lead to delays in treatment, which reduces the efficacy of treatment.
My interest lies in understanding how a person's genetic background affects their susceptibility to chemotherapy-induced toxicities. I use genetically diverse mouse models (i.e. Collaborative Cross and Diversity Outbred) to find genes that influence the variation in susceptibility to these toxicities. The goal of this work is to translate these genes to the clinic by creating genetic tests to predict toxicity and discovering new therapies to prevent toxicity.